556 related articles for article (PubMed ID: 15254419)
1. The PIK3CA gene is mutated with high frequency in human breast cancers.
Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
[TBL] [Abstract][Full Text] [Related]
2. PI3K: Missense Mutation Motivates Malignancy.
Hawthorne VS; Yu D
Cancer Biol Ther; 2004 Aug; 3(8):776-7. PubMed ID: 15280668
[No Abstract] [Full Text] [Related]
3. PIK3CA mutations in in situ and invasive breast carcinomas.
Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma.
Firoozinia M; Zareian Jahromi M; Moghadamtousi SZ; Nikzad S; Abdul Kadir H
Int J Med Sci; 2014; 11(6):620-5. PubMed ID: 24782652
[TBL] [Abstract][Full Text] [Related]
5. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
6. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Wu G; Xing M; Mambo E; Huang X; Liu J; Guo Z; Chatterjee A; Goldenberg D; Gollin SM; Sukumar S; Trink B; Sidransky D
Breast Cancer Res; 2005; 7(5):R609-16. PubMed ID: 16168105
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutations of PIK3CA in human cancers.
Samuels Y; Velculescu VE
Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
Kandula M; Chennaboina KK; Ys AR; Raju S
Asian Pac J Cancer Prev; 2013; 14(9):5067-72. PubMed ID: 24175777
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract][Full Text] [Related]
12. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Levine DA; Bogomolniy F; Yee CJ; Lash A; Barakat RR; Borgen PI; Boyd J
Clin Cancer Res; 2005 Apr; 11(8):2875-8. PubMed ID: 15837735
[TBL] [Abstract][Full Text] [Related]
13. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.
Michelucci A; Di Cristofano C; Lami A; Collecchi P; Caligo A; Decarli N; Leopizzi M; Aretini P; Bertacca G; Porta RP; Ricci S; Della Rocca C; Stanta G; Bevilacqua G; Cavazzana A
Diagn Mol Pathol; 2009 Dec; 18(4):200-5. PubMed ID: 19861897
[TBL] [Abstract][Full Text] [Related]
15. Initiating breast cancer by PIK3CA mutation.
Miller TW
Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Isakoff SJ; Engelman JA; Irie HY; Luo J; Brachmann SM; Pearline RV; Cantley LC; Brugge JS
Cancer Res; 2005 Dec; 65(23):10992-1000. PubMed ID: 16322248
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
19. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Dumont AG; Dumont SN; Trent JC
Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]